Quick Answer
Cartesian Therapeutics, Inc. reported Diluted EPS of $5.02 per share (loss) for fiscal year 2025.
Cartesian Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$5.02 | -11.8% |
| 2024 | -$4.49 | +91.0% |
| 2023 | -$49.76 | -49860.0% |
| 2022 | $0.10 | +145.5% |
| 2021 | -$0.22 | +67.6% |
| 2020 | -$0.68 | +44.3% |
| 2019 | -$1.22 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.38 | -22.1% | -376.0% |
| June 30, 2025 | $0.50 | -7.4% | +173.5% |
| March 31, 2025 | -$0.68 | +93.5% | +39.8% |
| September 30, 2024 | -$1.13 | +35.1% | -309.3% |
| June 30, 2024 | $0.54 | +124.2% | +105.1% |
| March 31, 2024 | -$10.50 | -147.6% | -503.4% |
| September 30, 2023 | -$1.74 | -3380.0% | +22.0% |
| June 30, 2023 | -$2.23 | -3816.7% | +47.4% |
- Cartesian Therapeutics, Inc. showed a decrease of -11.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Cartesian Therapeutics, Inc.’s diluted eps has declined by 311.5% (from $1.22 per share (loss) to $5.02 per share (loss)).
- The most recent figure is from Cartesian Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: